• Global Phase 3 clinical study completed
• Plan to file MA with FDA/EMA in 2024 H1
• Partners – Hikma (US), Pharmapark (Russia and CIS countries)
Biological Drug Product, Formulation, mAb Formulation
Ustekinumab (Stelara®) biosimilar
Related products
-
FormulationRecombinant Teriparatide for Injection
-
-
Chemical Drug ProductTirzepatide Injection (single-dose)(Mounjaro,Zepbound)
Indications:Glycemic Control,Weight Management
-